Skip to content

Innoviva, Inc. INVA Current ratio

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Merck & Co. logo
Merck & Co.MRK
1.3×-0.1×
AbbVie logo
AbbVieABBV
0.8×0.0×
Insmed logo
InsmedINSM
4.5×-1.4×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
4.1×-5.6×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
14×-0.4×

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.4B+9.7%
P/E3.5×
P/S4.1×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s current ratio?
Innoviva, Inc. (INVA) reported current ratio of 21.1× in Q1 2026.
How has Innoviva, Inc.'s current ratio changed year-over-year?
Innoviva, Inc.'s current ratio increased by 752.4% year-over-year, from 2.5× to 21.1×.
What is the long-term trend for Innoviva, Inc.'s current ratio?
Over 5 years (2020 to 2025), Innoviva, Inc.'s current ratio has grown at a -23.5% compound annual growth rate (CAGR), from 56× to 14.6×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.